ASLAN Pharmaceuticals Limited - ADR
$0.60
$--
(--%)
As on 16-Aug-2024 09:30EDT
Market cap
$2 Mln
Revenue (TTM)
$12 Mln
P/E Ratio
--
P/B Ratio
2.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-2 Mln
-
ROE
-4.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.4
-
Debt to Equity
-1.1
-
Book Value
$--
-
EPS
$-30.3
-
Face value
--
-
Shares outstanding
2,828,350
10 Years Aggregate
CFO
$-257.10 Mln
EBITDA
$-293.76 Mln
Net Profit
$-307.87 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
ASLAN Pharmaceuticals - ADR
| -85.6 | -56.5 | -81.3 | -96.4 | -82.6 | -64.6 | -- |
|
BSE Sensex*
| -8.8 | 2.8 | 3.6 | -6.3 | 6.7 | 8.0 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|
|
ASLAN Pharmaceuticals - ADR
| -71.0 | -67.9 | -38.8 | -9.9 | -43.6 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
ASLAN Pharmaceuticals - ADR
|
0.6 | 1.7 | 12.0 | -35.0 | -184.0 | -- | -- | 2.1 |
| 45.0 | 8,191.5 | 16.5 | -460.5 | -2,791.7 | -110 | -- | 14.5 |
Shareholding Pattern
View DetailsAbout ASLAN Pharmaceuticals - ADR
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal... antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore. Read more
-
Founder, CEO & Executive Director
Dr. Carl Alan Jason Morton Firth EMBA, Ph.D.
-
Founder, CEO & Executive Director
Dr. Carl Alan Jason Morton Firth EMBA, Ph.D.
-
Headquarters
Singapore
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for ASLAN Pharmaceuticals - ADR
What is the current share price of ASLAN Pharmaceuticals Limited - ADR Today?
The share price of ASLAN Pharmaceuticals Limited - ADR is $0.60 (NASDAQ) as of 16-Aug-2024 09:30 EDT. ASLAN Pharmaceuticals Limited - ADR has given a return of -82.56% in the last 3 years.
What is the current PB & PE ratio of ASLAN Pharmaceuticals Limited - ADR?
Since, TTM earnings of ASLAN Pharmaceuticals Limited - ADR is negative, P/E ratio is not available.
The P/B ratio of ASLAN Pharmaceuticals Limited - ADR is 2.14 times as on 16-Aug-2024, a 50 discount to its peers’ median range of 4.30 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-5.19
|
-17.28
|
|
2022
|
0.00
|
0.02
|
|
2021
|
-0.02
|
0.01
|
|
2020
|
-0.04
|
-0.07
|
|
2019
|
-0.29
|
-8.17
|
What is the 52 Week High and Low of ASLAN Pharmaceuticals Limited - ADR?
The 52-week high and low of ASLAN Pharmaceuticals Limited - ADR are Rs -- and Rs -- as of 22-Jun-2026.
What is the market cap of ASLAN Pharmaceuticals Limited - ADR?
ASLAN Pharmaceuticals Limited - ADR has a market capitalisation of $ 2 Mln as on 16-Aug-2024. As per SEBI classification, it is a Small Cap company.
Should I invest in ASLAN Pharmaceuticals Limited - ADR?
Before investing in ASLAN Pharmaceuticals Limited - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.